Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 41
Filter
1.
Med Mycol Case Rep ; 42: 100599, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37727452

ABSTRACT

We present a case of laryngeal cryptococcosis caused by cryptococcosis neoformans var. grubii affecting a patient using excessive inhaled corticosteroids. The patient experienced symptoms for several months prior to specialist review and the visualization of a mass lesion by nasopharyngoscopy. Fortunately a biopsy was performed and through histopathology & microbiological assessment a diagnosis of cryptococcal laryngitis was made. Treatment with 6 months of fluconazole resulted in clinical cure and resolution of symptoms. It is important to raise awareness of the risk of non-Candida fungal infections in patients on high dose corticosteroids, especially in the post covid era were steroids are more commonly prescribed.

3.
QJM ; 112(1): 17-21, 2019 Jan 01.
Article in English | MEDLINE | ID: mdl-30295832

ABSTRACT

AIM: To evaluate prior prevalence of HIV indicator conditions in late-presenters with HIV infection. DESIGN: Retrospective cohort study between 2000 and 2014 in a healthcare network in Melbourne, Australia comparing patients presenting with late diagnosis of HIV infection (CD4 < 350 cells/ml) to those patients who had a CD greater than or equal to 350 cells/ml at presentation. METHOD: The European AIDS Clinical Society guidelines on HIV indicator guided testing were used to assess for any indicator conditions in their prior medical history which may have represented a missed opportunity for earlier diagnosis. Main outcome measures: Descriptive statistics and prevalence of HIV indicator conditions. RESULTS: Of 436 patients with HIV infection, 82 were late presenters. Late presenters were more commonly male (83% vs. 75%, P = 0.11), older (mean age 45 vs. 39 years), born overseas (61% vs. 58%, P = 0.68) and report heterosexual transmission as their exposure risk (51% vs. 31%, P < 0.001). Of 80 patients with late presentation of HIV infection, 54 (55%) had at least one, 29 (36%) at least 2, 12 (15%) at least 3 and 5 (6%) had 4 or more previous HIV indicator conditions which would have triggered HIV testing according to guidelines. The most common indicator conditions were: unexplained loss of weight (31%), herpes zoster (10%), thrombocytopenia or leukopenia (10%), oral or oesophageal candidiasis (10%) and community acquired pneumonia (9%). Twenty patients (25%) had HIV indicator conditions diagnosed at least 12 months before the eventual diagnosis of HIV infection. DISCUSSION/ CONCLUSION: Patients diagnosed with late-presenting HIV often had an HIV indicator condition prior to presentation, presenting a missed opportunity for earlier diagnosis.


Subject(s)
Delayed Diagnosis/statistics & numerical data , HIV Infections/diagnosis , HIV Infections/epidemiology , Adolescent , Adult , Aged , Aged, 80 and over , Australia/epidemiology , CD4 Lymphocyte Count , Candidiasis/complications , Child , Community-Acquired Infections/complications , Early Diagnosis , Female , HIV Infections/complications , Herpes Zoster/complications , Humans , Leukopenia/complications , Male , Middle Aged , Pneumonia/complications , Prevalence , Retrospective Studies , Risk Factors , Thrombocytopenia/complications , Time Factors , Weight Loss , Young Adult
4.
Intern Med J ; 46(4): 479-93, 2016 Apr.
Article in English | MEDLINE | ID: mdl-27062204

ABSTRACT

The incidence of Clostridium difficile infection (CDI) continues to rise, whilst treatment remains problematic due to recurrent, refractory and potentially severe nature of disease. The treatment of C. difficile is a challenge for community and hospital-based clinicians. With the advent of an expanding therapeutic arsenal against C. difficile since the last published Australasian guidelines, an update on CDI treatment recommendations for Australasian clinicians was required. On behalf of the Australasian Society of Infectious Diseases, we present the updated guidelines for the management of CDI in adults and children.


Subject(s)
Clostridioides difficile , Clostridium Infections/epidemiology , Clostridium Infections/therapy , Disease Management , Practice Guidelines as Topic/standards , Societies, Medical/standards , Adult , Australasia/epidemiology , Australia/epidemiology , Clostridioides difficile/isolation & purification , Clostridium Infections/diagnosis , Communicable Diseases/diagnosis , Communicable Diseases/epidemiology , Communicable Diseases/therapy , Humans , New Zealand/epidemiology , Societies, Medical/trends
5.
Clin Microbiol Infect ; 22(9): 775-781, 2016 Sep.
Article in English | MEDLINE | ID: mdl-26806139

ABSTRACT

Mucormycosis is the second most common cause of invasive mould infection and causes disease in diverse hosts, including those who are immuno-competent. We conducted a multicentre retrospective study of proven and probable cases of mucormycosis diagnosed between 2004-2012 to determine the epidemiology and outcome determinants in Australia. Seventy-four cases were identified (63 proven, 11 probable). The majority (54.1%) were caused by Rhizopus spp. Patients who sustained trauma were more likely to have non-Rhizopus infections relative to patients without trauma (OR 9.0, p 0.001, 95% CI 2.1-42.8). Haematological malignancy (48.6%), chemotherapy (42.9%), corticosteroids (52.7%), diabetes mellitus (27%) and trauma (22.9%) were the most common co-morbidities or risk factors. Rheumatological/autoimmune disorders occurred in nine (12.1%) instances. Eight (10.8%) cases had no underlying co-morbidity and were more likely to have associated trauma (7/8; 87.5% versus 10/66; 15.2%; p <0.001). Disseminated infection was common (39.2%). Apophysomyces spp. and Saksenaea spp. caused infection in immuno-competent hosts, most frequently associated with trauma and affected sites other than lung and sinuses. The 180-day mortality was 56.7%. The strongest predictors of mortality were rheumatological/autoimmune disorder (OR = 24.0, p 0.038 95% CI 1.2-481.4), haematological malignancy (OR = 7.7, p 0.001, 95% CI 2.3-25.2) and admission to intensive care unit (OR = 4.2, p 0.02, 95% CI 1.3-13.8). Most deaths occurred within one month. Thereafter we observed divergence in survival between the haematological and non-haematological populations (p 0.006). The mortality of mucormycosis remains particularly high in the immuno-compromised host. Underlying rheumatological/autoimmune disorders are a previously under-appreciated risk for infection and poor outcome.


Subject(s)
Mucormycosis/epidemiology , Adolescent , Adult , Aged , Australia/epidemiology , Comorbidity , Disease Management , Disease Susceptibility , Female , Humans , Male , Middle Aged , Mucormycosis/diagnosis , Mucormycosis/etiology , Mucormycosis/therapy , Patient Outcome Assessment , Retrospective Studies , Young Adult
6.
Eur J Clin Microbiol Infect Dis ; 35(1): 49-55, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26490139

ABSTRACT

Healthcare-associated Staphylococcus aureus bacteremia (HA-SAB) is an increasingly frequently observed complication of medical treatment. Current guidelines recommend evaluation with echocardiography and preferably transesophageal echocardiography for the exclusion of infectious endocarditis (IE). We performed a retrospective analysis of all patients with HA-SAB between 1 January 2007 and 31 July 2012. Patients were divided into those with a high degree of clinical suspicion of IE (prosthetic intracardiac device, hemodialysis or positive blood cultures for 4 days or more) or those with a low degree of clinical suspicion of IE (absence of high-risk features based on previous literature as strong indicators of endocarditis). Three hundred and fifty-eight patients with HA-SAB were evaluated to determine the prevalence of IE, including 298 (83 %) who had echocardiography. Fourteen patients (4 %) had a final diagnosis of IE after echocardiography. In the group with a high degree of clinical suspicion 11 out of 84 patients (13 %) had IE. In the group with a low degree of clinical suspicion group 3 out 274 patients (1.1 %) had IE. HA-SAB has a low rate of IE, especially in the absence of high-risk features such as prolonged bacteremia, intracardiac prosthetic devices, and hemodialysis. Echocardiographic imaging in this low-risk population of patients is rarely helpful and may generally be avoided, although careful clinical follow-up is warranted. Patients with HA-SAB who have mechanical valves, intracardiac devices, prolonged bacteremia or dialysis dependency have a high incidence of IE and should be evaluated thoroughly using echocardiography.


Subject(s)
Bacteremia/complications , Cross Infection/epidemiology , Diagnostic Tests, Routine , Echocardiography , Endocarditis, Bacterial/epidemiology , Staphylococcal Infections/epidemiology , Adolescent , Adult , Aged , Aged, 80 and over , Cross Infection/microbiology , Endocarditis, Bacterial/diagnosis , Female , Humans , Male , Middle Aged , Prevalence , Retrospective Studies , Staphylococcal Infections/diagnosis , Young Adult
7.
Euro Surveill ; 20(10): 21059, 2015 Mar 12.
Article in English | MEDLINE | ID: mdl-25788254

ABSTRACT

We describe an Australia-wide Clostridium difficile outbreak in 2011 and 2012 involving the previously uncommon ribotype 244. In Western Australia, 14 of 25 cases were community-associated, 11 were detected in patients younger than 65 years, 14 presented to emergency/outpatient departments, and 14 to non-tertiary/community hospitals. Using whole genome sequencing, we confirm ribotype 244 is from the same C. difficile clade as the epidemic ribotype 027. Like ribotype 027, it produces toxins A, B, and binary toxin, however it is fluoroquinolone-susceptible and thousands of single nucleotide variants distinct from ribotype 027. Fifteen outbreak isolates from across Australia were sequenced. Despite their geographic separation, all were genetically highly related without evidence of geographic clustering, consistent with a point source, for example affecting the national food chain. Comparison with reference laboratory strains revealed the outbreak clone shared a common ancestor with isolates from the United States and United Kingdom (UK). A strain obtained in the UK was phylogenetically related to our outbreak. Follow-up of that case revealed the patient had recently returned from Australia. Our data demonstrate new C. difficile strains are an on-going threat, with potential for rapid spread. Active surveillance is needed to identify and control emerging lineages.


Subject(s)
Clostridioides difficile/genetics , Communicable Diseases, Emerging/epidemiology , Enterocolitis, Pseudomembranous/epidemiology , Genome, Bacterial/genetics , Adult , Aged , Aged, 80 and over , Bacterial Proteins/genetics , Bacterial Toxins/genetics , Communicable Diseases, Emerging/microbiology , Disease Outbreaks , Enterocolitis, Pseudomembranous/microbiology , Humans , Male , Middle Aged , Phylogeny , Polymorphism, Single Nucleotide , Population Surveillance , Prevalence , Ribotyping , Severity of Illness Index , Western Australia/epidemiology
9.
Clin Microbiol Infect ; 21(5): 490.e1-10, 2015 May.
Article in English | MEDLINE | ID: mdl-25677259

ABSTRACT

The epidemiology of invasive fungal disease (IFD) due to filamentous fungi other than Aspergillus may be changing. We analysed clinical, microbiological and outcome data in Australian patients to determine the predisposing factors and identify determinants of mortality. Proven and probable non-Aspergillus mould infections (defined according to modified European Organization for Research and Treatment of Cancer/Mycoses Study Group criteria) from 2004 to 2012 were evaluated in a multicentre study. Variables associated with infection and mortality were determined. Of 162 episodes of non-Aspergillus IFD, 145 (89.5%) were proven infections and 17 (10.5%) were probable infections. The pathogens included 29 fungal species/species complexes; mucormycetes (45.7%) and Scedosporium species (33.3%) were most common. The commonest comorbidities were haematological malignancies (HMs) (46.3%) diabetes mellitus (23.5%), and chronic pulmonary disease (16%); antecedent trauma was present in 21% of cases. Twenty-five (15.4%) patients had no immunocompromised status or comorbidity, and were more likely to have acquired infection following major trauma (p <0.01); 61 (37.7%) of cases affected patients without HMs or transplantation. Antifungal therapy was administered to 93.2% of patients (median 68 days, interquartile range 19-275), and adjunctive surgery was performed in 58.6%. The all-cause 90-day mortality was 44.4%; HMs and intensive-care admission were the strongest predictors of death (both p <0.001). Survival varied by fungal group, with the risk of death being significantly lower in patients with dematiaceous mould infections than in patients with other non-Aspergillus mould infections. Non-Aspergillus IFD affected diverse patient groups, including non-immunocompromised hosts and those outside traditional risk groups; therefore, definitions of IFD in these patients are required. Given the high mortality, increased recognition of infections and accurate identification of the causative agent are required.


Subject(s)
Fungemia/epidemiology , Fungemia/microbiology , Fungi/classification , Fungi/isolation & purification , Meningitis, Fungal/epidemiology , Meningitis, Fungal/microbiology , Adolescent , Adult , Aged , Aged, 80 and over , Antifungal Agents , Australia/epidemiology , Child , Comorbidity , Fungemia/mortality , Fungemia/therapy , Humans , Male , Meningitis, Fungal/mortality , Meningitis, Fungal/therapy , Middle Aged , Retrospective Studies , Risk Factors , Surgical Procedures, Operative , Survival Analysis , Young Adult
10.
Intern Med J ; 45(1): 113-5, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25582941

ABSTRACT

This cross-sectional survey of patients with adverse drug reactions (ADR) to penicillin and their treating doctor, nurse and pharmacist was undertaken to identify the extent of healthcare workers (HCW) awareness of their patients' ADR, and antibiotic use in hospital. There were 23 (38%) doctors, 53 (87%) nurses and 40 (66%) pharmacists who were aware of their patient's penicillin ADR, despite more than half of their patients receiving antibiotics. Interventions encouraging 'double checking' may improve antibiovigilance.


Subject(s)
Attitude of Health Personnel , Drug-Related Side Effects and Adverse Reactions/diagnosis , Health Personnel/standards , Penicillins/adverse effects , Professional Competence/standards , Cross-Sectional Studies , Drug-Related Side Effects and Adverse Reactions/epidemiology , Humans , Incidence , Surveys and Questionnaires , Victoria/epidemiology
11.
J Clin Microbiol ; 53(2): 626-35, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25520446

ABSTRACT

Eggerthella lenta is an emerging pathogen that has been underrecognized due to historical difficulties with phenotypic identification. Until now, its pathogenicity, antimicrobial susceptibility profile, and optimal treatment have been poorly characterized. In this article, we report the largest cohort of patients with E. lenta bacteremia to date and describe in detail their clinical features, microbiologic characteristics, treatment, and outcomes. We identified 33 patients; the median age was 68 years, and there was no gender predominance. Twenty-seven patients (82%) had serious intra-abdominal pathology, often requiring a medical procedure. Of those who received antibiotics (28/33, 85%), the median duration of treatment was 21.5 days. Mortality from all causes was 6% at 7 days, 12% at 30 days, and 33% at 1 year. Of 26 isolates available for further testing, all were identified as E. lenta by both commercially available matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) systems, and none were found to harbor a vanA or vanB gene. Of 23 isolates which underwent susceptibility testing, all were susceptible to amoxicillin-clavulanate, cefoxitin, metronidazole, piperacillin-tazobactam, ertapenem, and meropenem, 91% were susceptible to clindamycin, 74% were susceptible to moxifloxacin, and 39% were susceptible to penicillin.


Subject(s)
Actinobacteria/isolation & purification , Bacteremia/microbiology , Bacteremia/pathology , Gram-Positive Bacterial Infections/microbiology , Gram-Positive Bacterial Infections/pathology , Actinobacteria/chemistry , Actinobacteria/classification , Actinobacteria/genetics , Adolescent , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Bacteremia/drug therapy , Bacteremia/mortality , Child , Female , Genes, Bacterial , Gram-Positive Bacterial Infections/drug therapy , Gram-Positive Bacterial Infections/mortality , Humans , Male , Microbial Sensitivity Tests , Middle Aged , Retrospective Studies , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , Survival Analysis , Treatment Outcome , Young Adult
13.
Mycoses ; 57(5): 316-9, 2014 May.
Article in English | MEDLINE | ID: mdl-24251958

ABSTRACT

Infective endocarditis due to Candida sp. has a high mortality rate. Traditionally, management involves early surgery and prolonged amphotericin ± flucytosine. We report a case of Candida parapsilosis bileaflet mitral valve endocarditis cured with anidulafungin and fluconazole, and review the role of echinocandins in the management of Candida endocarditis.


Subject(s)
Antifungal Agents/therapeutic use , Candida/isolation & purification , Endocarditis/drug therapy , Endocarditis/microbiology , Anidulafungin , Candida/physiology , Echinocandins/therapeutic use , Fluconazole/therapeutic use , Humans , Male , Middle Aged
14.
J Hosp Infect ; 85(4): 289-96, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24161798

ABSTRACT

BACKGROUND: Vancomycin-resistant enterococci (VRE) colonization is a frequent occurrence in patients with renal failure. Understanding the impact of VRE colonization on this group of patients has considerable clinical applicability. AIM: To understand whether VRE colonization in renal patients has an impact on number of admissions to hospital, length of stay, and mortality. METHODS: A retrospective case-control study of renal dialysis patients was performed between 2000 and 2010. Cases were 134 VRE-colonized patients requiring renal replacement therapy and matched controls were 137 non-colonized patients with the same baseline characteristics. Matched cases and controls were analysed for differences in number of admissions, length of stay, and mortality. FINDINGS: There was no difference in mortality between colonized and non-colonized patients (hazard ratio: 1.14; 95% confidence interval: 0.78-1.69; P = 0.49). Length of stay for colonized patients was 7.29 days compared with 4.14 days (P < 0.001). The number of admissions for VRE-colonized patients was not significantly different compared with controls (9.34 vs 8.33, P = 0.78). CONCLUSION: VRE colonization did not increase mortality in renal patients but did contribute to increased length of stay.


Subject(s)
Carrier State/microbiology , Enterococcus/drug effects , Gram-Positive Bacterial Infections/complications , Gram-Positive Bacterial Infections/microbiology , Kidney Failure, Chronic/mortality , Vancomycin Resistance , Adult , Aged , Aged, 80 and over , Case-Control Studies , Enterococcus/isolation & purification , Female , Hospitalization , Humans , Length of Stay , Male , Middle Aged , Retrospective Studies , Survival Analysis , Young Adult
15.
Clin Microbiol Infect ; 19(12): 1163-8, 2013 Dec.
Article in English | MEDLINE | ID: mdl-23441652

ABSTRACT

We reported an association between elevated vancomycin MIC and 30-day mortality in patients with Staphylococcus aureus bacteraemia (SAB), including patients with methicillin-susceptible S. aureus (MSSA) treated with flucloxacillin. A detailed analysis of comorbidities and disease severity scores in the same cohort of patients was performed to ascertain if unknown clinical parameters may have influenced these results. The association between elevated vancomycin MIC and 30-day mortality in SAB remained significant (p 0.001) on multivariable logistic regression analysis even when accounting for clinical factors. In addition, the association persisted when restricting analysis to patients with MSSA bacteraemia treated with flucloxacillin. This suggests that elevated vancomycin MIC is associated with but not causally linked to an organism factor that is responsible for increased mortality.


Subject(s)
Anti-Bacterial Agents/pharmacology , Bacteremia/mortality , Methicillin-Resistant Staphylococcus aureus/drug effects , Staphylococcal Infections/drug therapy , Staphylococcal Infections/mortality , Staphylococcus aureus/drug effects , Vancomycin/pharmacology , Adolescent , Adult , Aged , Anti-Bacterial Agents/therapeutic use , Bacteremia/drug therapy , Bacteremia/microbiology , Child , Child, Preschool , Comorbidity , Female , Humans , Infant , Infant, Newborn , Logistic Models , Male , Microbial Sensitivity Tests , Middle Aged , Retrospective Studies , Staphylococcal Infections/microbiology , Treatment Outcome , Vancomycin/therapeutic use , Young Adult
16.
Intern Med J ; 42(2): 202-4, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22356494

ABSTRACT

We describe three new diagnosis of HIV infection as a direct result of testing following occupational exposures (NSIs) in a low-prevalence setting. In each case the finding was unexpected. Our series provides a reminder of the importance of prompt reporting of NSIs by healthcare workers, access to rapid HIV testing and post-exposure prophylaxis with antiretrovirals to prevent transmission.


Subject(s)
HIV Infections/diagnosis , Health Personnel , Needlestick Injuries/diagnosis , Occupational Exposure/adverse effects , Risk Management/methods , Adult , HIV Infections/etiology , Humans , Male , Needlestick Injuries/complications
17.
Infection ; 40(3): 319-21, 2012 Jun.
Article in English | MEDLINE | ID: mdl-21877181

ABSTRACT

The etiology of culture-negative septic arthritis is poorly characterised in persons infected with human immunodeficiency virus (HIV). New molecular methods may assist in the investigation of culture-negative infections of sterile sites, including septic arthritis. We describe the first case of septic arthritis due to the cause of rat bite fever (RBF), Streptobacillus moniliformis, confirmed by 16S rRNA sequence analysis, in a patient with newly diagnosed HIV infection.


Subject(s)
Acquired Immunodeficiency Syndrome/complications , Anti-Bacterial Agents/therapeutic use , Arthritis, Infectious/drug therapy , Doxycycline/therapeutic use , Penicillin G/therapeutic use , Rat-Bite Fever/drug therapy , Streptobacillus/isolation & purification , Adult , Animals , Arthritis, Infectious/diagnosis , Arthritis, Infectious/microbiology , Humans , Male , Rat-Bite Fever/diagnosis , Rat-Bite Fever/transmission , Rats , Treatment Outcome
19.
Eur J Clin Microbiol Infect Dis ; 28(8): 963-70, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19357879

ABSTRACT

The purpose of this study was to examine the rate and clinical consequences of nalidixic acid-resistant (NAR) isolates in travellers with enteric fever presenting to a hospital in a developed country. We retrospectively examined microbiologically confirmed cases of enteric fever in adult returned travellers over an 18-year period presenting to two tertiary referral hospitals in Melbourne, Australia. There were 59 cases of Salmonella typhi infection, 43 cases of S. paratyphi A infection and two cases of S. paratyphi B infection. Most patients reported recent travel to India (36%) or Indonesia (29%). NAR isolates were commonly encountered (41% of all isolates), particularly from India (75%), Pakistan (80%) and Bangladesh (60%). The number of NAR isolates increased progressively after 2003. Patients with NAR isolates had prolonged mean fever clearance time (5.6 vs. 3.3 days, P = 0.03) and prolonged hospital stay (7.9 vs. 5.7 days, P = 0.02) compared to non-resistant isolates. This represents the largest report of NAR enteric fever in returned travellers. NAR isolates predominate in cases of enteric fever from South Asia and result in prolonged fever clearance time and hospital stay. Empiric therapy with alternative antibiotics such as ceftriaxone or azithromycin should be considered in patients with suspected enteric fever from this region.


Subject(s)
Anti-Bacterial Agents/pharmacology , Drug Resistance, Bacterial , Nalidixic Acid/pharmacology , Paratyphoid Fever/microbiology , Salmonella paratyphi A/drug effects , Salmonella paratyphi B/drug effects , Salmonella typhi/drug effects , Travel , Typhoid Fever/microbiology , Adolescent , Adult , Aged , Animals , Australia , Female , Hospitalization , Humans , Length of Stay/statistics & numerical data , Male , Middle Aged , Paratyphoid Fever/physiopathology , Rats , Salmonella paratyphi A/isolation & purification , Salmonella paratyphi B/isolation & purification , Salmonella typhi/isolation & purification , Typhoid Fever/physiopathology , Young Adult
20.
J Hosp Infect ; 67(3): 245-52, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17942187

ABSTRACT

Acinetobacter has recently risen in prominence as a nosocomial pathogen, particularly due to increasing antibiotic resistance. The aim of this study was to describe changes in rates and antibiotic susceptibility patterns of Acinetobacter in three Melbourne hospitals. This was a retrospective review of microbiology records over five years. The rates of new clinical isolates of Acinetobacter per 10 000 discharges per quarter were calculated. Other information collected included antibiotic susceptibility patterns, age, gender, length of stay and ward [intensive care unit (ICU) or non-ICU]. Rates increased substantially at two hospitals, but not at the third. Increasing numbers at one hospital were associated with antibiotic resistance. Most first isolates were identified while the patient was in the ICU. Many isolates were from respiratory specimens, although a significant proportion was from blood. This study documents the establishment of Acinetobacter as a nosocomial pathogen in two Melbourne hospitals and serves as a warning for the future.


Subject(s)
Acinetobacter Infections/epidemiology , Acinetobacter Infections/microbiology , Acinetobacter/isolation & purification , Cross Infection/epidemiology , Cross Infection/microbiology , Adolescent , Adult , Aged , Aged, 80 and over , Australia/epidemiology , Bacteremia/microbiology , Critical Care , Drug Resistance, Bacterial , Female , Hospitals , Humans , Incidence , Longitudinal Studies , Male , Microbial Sensitivity Tests , Middle Aged , Respiratory Tract Diseases/microbiology , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...